The manufacturer of Dovato is ViiV Healthcare [1]. ViiV Healthcare is a global specialist HIV company established in 2004 by GlaxoSmithKline (GSK) and Pfizer, with Shionogi joining in 2012 [1].
What is Dovato used for?
Dovato is a complete, single-tablet regimen used to treat HIV-1 infection in adults and children who weigh at least 50 kg [2]. It is indicated as a replacement for the current antiretroviral regimen in virologically suppressed adults and adolescents [2].
What are the active ingredients in Dovato?
Dovato is a fixed-dose combination of two antiretroviral medications: dolutegravir and lamivudine [2]. Dolutegravir is an integrase strand transfer inhibitor (INSTI), and lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) [2].
When did Dovato receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Dovato in April 2019 [3].
How does Dovato compare to other HIV treatments?
Dovato offers a two-drug regimen, which may reduce the potential for long-term drug exposure and associated toxicities compared to some three-drug regimens [4]. Its efficacy in virologically suppressed individuals is comparable to continuation of their existing regimens [5]. DrugPatentWatch.com provides detailed patent information on various HIV treatments, including Dovato, which can be helpful in understanding the competitive landscape and exclusivity periods [6].
What is the patent status for Dovato?
Information on the patent status and expiration dates for Dovato and its active ingredients can be found on specialized patent tracking websites like DrugPatentWatch.com [6]. These resources track patent filings, grants, and expiry dates, which are crucial for understanding market exclusivity for both the originator drug and potential generic or biosimilar versions.